SNORD114-20: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD114-20

NCBI ID: G767598

SNORD114-20

Other Name(s): small nucleolar RNA, C/D box 114-20 | 14q(II-20) | Small nucleolar RNA, C/D box 114-20

SNORD114-20: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help maintain the stability of the endoplasmic reticulum by binding to specific protein -coding genes and promoting their retention in the reticulum. One of the well-known snRNAs is SNORD114-20, which is a 20-nt RNA molecule located in the C/D box region of the 114th gene on the X chromosome.

SNORD114-20 has been identified as a potential drug target and biomarker due to its unique structure and biochemical properties. Firstly, SNORD114-20 is a small molecule, which means it has a low molecular weight and can be easily synthesized and purified. Secondly, the C/D box region of SNORD114-20 is rich in conserved amino acid sequence, which suggests that it may have a stable structure and can interact with other molecules. Finally, the SNORD114-20 gene is located in the X chromosome, which means that it is only expressed in females and is subject to gender-specific regulation.

In addition to its potential drug-targeting properties, SNORD114-20 also has potential as a biomarker for a variety of diseases. One of the main applications of SNORD114-20 is its ability to cross-react with other snRNAs, which suggests that it may be a versatile marker for studying snRNA interactions and gene regulation. For example, studies have shown that SNORD114-20 can be used as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Another potential application of SNORD114-20 is its role in the regulation of cellular processes that are relevant to a variety of diseases, including cancer. Cancer is a complex disease that is characterized by the uncontrolled growth and proliferation of cells. One of the key factors that promote the growth of cancer cells is the production of too many RNA molecules, which can act as genetic templates for the cell's growth and division. SNORD114-20 has been shown to play a role in regulating the production of these RNA molecules, which may be a potential target for cancer therapies.

Finally, SNORD114-20 may also be a potential biomarker for diseases that are characterized by the breakdown of cellular organization and the formation of aggregates. diseases such as Alzheimer's disease and Parkinson's disease are characterized by the accumulation of neurofibrillary tangles and amyloid plaques, which can cause the brain to become abnormally organized and to interfere with its normal function. SNORD114-20 has been shown to play a role in regulating the production of these aggregates, which may be a potential target for therapies aimed at reducing the accumulation of these harmful structures in the brain.

In conclusion, SNORD114-20 is a small nucleolar RNA molecule that has a unique structure and biochemical properties that make it a promising candidate for drug targeting and biomarker. Its low molecular weight, stable C/D box region, and gender-specific regulation on the X chromosome make it a versatile molecule for a variety of applications. The potential applications of SNORD114-20 include the regulation of gene expression, the production of RNA molecules, the regulation of cellular organization, and the formation of aggregates. Further research is needed to fully understand the role of SNORD114-20 in disease and to develop effective therapies aimed at targeting it.

Protein Name: Small Nucleolar RNA, C/D Box 114-20

The "SNORD114-20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets